A Study on Weight Management for Obesity or Overweight
This study is looking into how well macupatide and eloralintide, either alone or together, can help adults with obesity or who are overweight manage their weight. Researchers will compare these treatments to a placebo (an inactive substance) to see if they help people lose weight and if they are safe. You might be able to join if you are between 18 and 75 years old and have obesity or are overweight, but you cannot have type 1 or type 2 diabetes. The main goal is to see the percentage of body weight change after 36 weeks. The current status of this study is unclear.
- Study design
- This interventional study plans to include 400 adult participants. It will compare macupatide and eloralintide, alone or in combination, against a placebo.
- What's involved
- Your participation in this study will last for about 64 weeks. The primary measurement of your body weight change will be taken at the beginning and at Week 36.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint for measuring body weight change is at Week 36.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
At a glance
Conditions
Where it's being run
40 sites across 20 statesStudy leadership
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Exclusion
What this trial measures
- Percent Change from Baseline in Body WeightBaseline, Week 36